Omega-3 polyunsaturated fatty acids reduce vascular endothelial growth factor production and suppress endothelial wound repair

Journal of Cardiovascular Translational Research

Volumn 6, Issue 2, 2013, Pages 287-293

  Zhuang, Wei ^a   Wang, Guo ^b   Li, Li ^a   Lin, Guoqiang ^a   Deng, Zhenyu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cardiovascular diseases; Polyunsaturated omega 3 fatty acid; Revascularisation; Vascular endothelial growth factor; Wound repair

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; MESSENGER RNA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CULTURE; CELL DEATH; CELL HYPOXIA; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; VASCULAR ENDOTHELIUM; WOUND HEALING; ANGIOGENESIS; APOPTOSIS; CELL LINE; DOSE RESPONSE; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TIME;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL HYPOXIA; CELL LINE; CELL PROLIFERATION; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EICOSAPENTAENOIC ACID; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84882953885     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9409-0     Document Type: Article

References (45)

1. Farhangkhoee, H.; Khan, Z. A.; Kaur, H.; Xin, X.; Chen, S.; Chakrabarti, S. (2006). Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. Pharmacology and Therapeutics, 111, 384-399.
2. Hadi, H. A.; Suwaidi, J. A. (2007). Endothelial dysfunction in diabetes mellitus. Vascular Health and Risk Management, 3, 853-876.
3. Ruschitzka, F.; Corti, R.; Noll, G.; Luscher, T. F. (1999). A rationale for treatment of endothelial dysfunction in hypertension. Journal of Hypertension. Supplement, 17, S25-S35.
4. Tang, E. H.; Vanhoutte, P. M. (2010). Endothelial dysfunction: a strategic target in the treatment of hypertension? Pflügers Archiv, 459, 995-1004.
5. Virdis, A.; Ghiadoni, L.; Giannarelli, C.; Taddei, S. (2010). Endothelial dysfunction and vascular disease in later life. Maturitas, 67, 20-24.
6. Mozaffarian, D.; Wu, J. H. (2011). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. Journal of the American College of Cardiology, 58, 2047-2067.
7. Cottin, S. C.; Sanders, T. A.; Hall, W. L. (2011). The differential effects of EPA and DHA on cardiovascular risk factors. Proceedings of the Nutrition Society, 70, 215-231.
8. von Schacky, C.; Harris, W. S. (2007). Cardiovascular benefits of omega-3 fatty acids. Cardiovascular Research, 73, 310-315.
9. Sala-Vila, A.; Harris, W. S.; Cofan, M.; Perez-Heras, A. M.; Pinto, X.; Lamuela-Raventos, R. M.; Covas, M. I.; Estruch, R.; Ros, E. (2011). Determinants of the omega-3 index in a Mediterranean population at increased risk for CHD. British Journal of Nutrition, 106, 425-431.
10. Tagawa, H.; Shimokawa, H.; Tagawa, T.; Kuroiwa-Matsumoto, M.; Hirooka, Y.; Takeshita, A. (1999). Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. Journal of Cardiovascular Pharmacology, 33, 633-640.
11. Bersot, T.; Haffner, S.; Harris, W. S.; Kellick, K. A.; Morris, C. M. (2006). Hypertriglyceridemia: management of atherogenic dyslipidemia. Journal of Family Practice, 55, S1-S8.
12. Mozaffarian, D.; Ascherio, A.; Hu, F. B.; Stampfer, M. J.; Willett, W. C.; Siscovick, D. S.; Rimm, E. B. (2005). Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation, 111, 157-164.
13. Geleijnse, J. M.; Giltay, E. J.; Grobbee, D. E.; Donders, A. R.; Kok, F. J. (2002). Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. Journal of Hypertension, 20, 1493-1499.
14. Wardhana, Surachmanto, E. S.; Datau, E. A. (2011). The role of omega-3 fatty acids contained in olive oil on chronic inflammation. Acta Medica Indonesiana, 43, 138-143.
15. MacLean, C. H.; Newberry, S. J.; Mojica, W. A.; Khanna, P.; Issa, A. M.; Suttorp, M. J.; Lim, Y. W.; Traina, S. B.; Hilton, L.; Garland, R.; Morton, S. C. (2006). Effects of omega-3 fatty acids on cancer risk: a systematic review. Journal of the American Medical Association, 295, 403-415.
16. Gleissman, H.; Johnsen, J. I.; Kogner, P. (2010). Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Experimental Cell Research, 316, 1365-1373.
17. Huang, T. L. (2010). Omega-3 fatty acids, cognitive decline, and Alzheimer's disease: a critical review and evaluation of the literature. Journal of Alzheimer's Disease, 21, 673-690.
18. Friedman, A. N. (2010). Omega-3 fatty acid supplementation in advanced kidney disease. Seminars in Dialysis, 23, 396-400.
19. Kajiguchi, M.; Kondo, T.; Izawa, H.; Kobayashi, M.; Yamamoto, K.; Shintani, S.; Numaguchi, Y.; Naoe, T.; Takamatsu, J.; Komori, K.; Murohara, T. (2007). Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. Circulation Journal, 71, 196-201.
20. Kalka, C.; Tehrani, H.; Laudenberg, B.; Vale, P. R.; Isner, J. M.; Asahara, T.; Symes, J. F. (2000). VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. The Annals of Thoracic Surgery, 70, 829-834.
21. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal, 13, 9-22.
22. Xiao, Y. F.; Ke, Q.; Chen, Y.; Morgan, J. P.; Leaf, A. (2004). Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells. Biochemical and Biophysical Research Communications, 321, 116-123.
23. Saito, J.; Terano, T.; Hirai, A.; Shiina, T.; Tamura, Y.; Saito, Y. (1997). Mechanisms of enhanced production of PGI2 in cultured rat vascular smooth muscle cells enriched with eicosapentaenoic acid. Atherosclerosis, 131, 219-228.
24. Costa, C.; Incio, J.; Soares, R. (2007). Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis, 10, 149-166.
25. Tonnesen, M. G.; Feng, X.; Clark, R. A. (2000). Angiogenesis in wound healing. The Journal of Investigative Dermatology. Symposium Proceedings, 5, 40-46.
26. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336.
27. Gardlik, R.; Celec, P.; Bernadic, M. (2011). Targeting angiogenesis for cancer (gene) therapy. Bratislavské Lekárske Listy, 112, 428-434.
28. Campa, C.; Harding, S. P. (2011). Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Current Drug Targets, 12, 173-181.
29. Arevalo, J. F.; Sanchez, J. G.; Wu, L.; Berrocal, M. H.; Alezzandrini, A. A.; Restrepo, N.; Maia, M.; Farah, M. E.; Brito, M.; Diaz-Llopis, M.; Rodriguez, F. J.; Reategui, G.; Iturralde-Iraola, J.; Udaondo-Mirete, P.; Pan-American Collaborative Retina Study Group. (2010). Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Ophthalmology, 117, 1974-1981. 1981.e1.
30. Bressler, N. M. (2009). Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology, 116, S15-S23.
31. Ozkiris, A. (2009). Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema. Eye (London, England), 23, 616-620.
32. Matesanz, N.; Park, G.; McAllister, H.; Leahey, W.; Devine, A.; McVeigh, G. E.; Gardiner, T. A.; McDonald, D. M. (2010). Docosahexaenoic acid improves the nitroso-redox balance and reduces VEGF-mediated angiogenic signaling in microvascular endothelial cells. Investigative Ophthalmology & Visual Science, 51, 6815-6825.
33. Brouwer, I. A. (2008). Omega-3 PUFA: good or bad for prostate cancer? Prostaglandins, Leukotrienes, and Essential Fatty Acids, 79, 97-99.
34. Escrich, E.; Solanas, M.; Moral, R.; Escrich, R. (2011). Modulatory effects and molecular mechanisms of olive oil and other dietary lipids in breast cancer. Current Pharmaceutical Design, 17, 813-830.
35. Henry, M.; Benjelloun, A.; Henry, I.; Polydorou, A.; Hugel, M. (2010). Renal angioplasty and stenting: is it still indicated after ASTRAL and STAR studies? The Journal of Cardiovascular Surgery, 51, 701-720.
36. Touze, E.; Trinquart, L.; Chatellier, G.; Mas, J. L. (2009). Systematic review of the perioperative risks of stroke or death after carotid angioplasty and stenting. Stroke, 40, e683-e693.
37. Takayama, T.; Hiro, T.; Hirayama, A. (2010). Is angioplasty able to become the gold standard of treatment beyond bypass surgery for patients with multivessel coronary artery disease? Therapeutic strategies for 3-vessel coronary artery disease: OPCAB vs PCI(PCI-Side). Circulation Journal, 74, 2744-2749.
38. Bloch, M. J.; Pickering, T. (2000). Renal vascular disease: medical management, angioplasty, and stenting. Seminars in Nephrology, 20, 474-488.
39. De Giovanni, J. V. (2007). Balloon angioplasty for branch pulmonary artery stenosis - cutting balloons. Catheterization and Cardiovascular Interventions, 69, 459-467.
40. Shah, K. B.; Han, D. P. (2004). Proliferative diabetic retinopathy. International Ophthalmology Clinics, 44, 69-84.
41. Caldwell, R. B.; Bartoli, M.; Behzadian, M. A.; El Remessy, A. E.; Al Shabrawey, M.; Platt, D. H.; Caldwell, R. W. (2003). Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes/Metabolism Research and Reviews, 19, 442-455.
42. Tateishi-Yuyama, E.; Matsubara, H.; Murohara, T.; Ikeda, U.; Shintani, S.; Masaki, H.; Amano, K.; Kishimoto, Y.; Yoshimoto, K.; Akashi, H.; Shimada, K.; Iwasaka, T.; Imaizumi, T. (2002). Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet, 360, 427-435.
43. Iwaguro, H.; Yamaguchi, J.; Kalka, C.; Murasawa, S.; Masuda, H.; Hayashi, S.; Silver, M.; Li, T.; Isner, J. M.; Asahara, T. (2002). Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation, 105, 732-738.
44. Rissanen, T. T.; Vajanto, I.; Yla-Herttuala, S. (2001). Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb - on the way to the clinic. European Journal of Clinical Investigation, 31, 651-666.
45. Chen, B. S.; Xie, H.; Zhang, S. L.; Geng, H. Q.; Zhou, J. M.; Pan, J.; Chen, F. (2011). Tissue engineering of bladder using vascular endothelial growth factor gene-modified endothelial progenitor cells. The International Journal of Artificial Organs, 34, 1137-1146.